Moderna pauses plan to build mRNA manufacturing facility in Kenya

The demand in Africa for COVID-19 vaccines has declined

Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals

Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry

Merck and Moderna initiate Phase 3 study evaluating V940 (mRNA-4157) in combination with Keytruda for treatment of non-small cell lung cancer

The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months

Nobel prize 2023 for medicine awarded to Katalin Karikó, Drew Weissman for research on mRNA vaccines to fight Covid-19

The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19

BioNTech and CEPI partnership to advance mRNA Mpox Vaccine development

The partnership is part of BioNTech’s strategy to develop novel prophylactic vaccines for the prevention of high-medical-need infectious diseases

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology

Takara Bio Europe launches high-quality enzymes suitable for pre-clinical mRNA vaccine

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials